» Articles » PMID: 34867400

Large Screening Identifies ACE2 Positively Correlates With NF-κB Signaling Activity and Targeting NF-κB Signaling Drugs Suppress ACE2 Levels

Overview
Journal Front Pharmacol
Date 2021 Dec 6
PMID 34867400
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Coronaviruses SARS-CoV-2 infected more than 156 million people and caused over 3 million death in the whole world, therefore a better understanding of the underlying pathogenic mechanism and the searching for more effective treatments were urgently needed. Angiotensin-converting enzyme 2 (ACE2) was the receptor for SARS-CoV-2 infection. In this study, we found that ACE2 was an interferon-stimulated gene (ISG) in human cell lines. By performing an ISG library screening, we found that ACE2 levels were positively regulated by multiple ISGs. Interestingly, ACE2 levels were highly correlated with ISGs-induced NF-κB activities, but not IFNβ levels. Furthermore, using an approved clinical durgs library, we found two clinical drugs, Cepharanthine and Glucosamine, significantly inhibited ACE2 level, IFNβ level, and NF-κB signaling downstream TNFα and IL6 levels. Our finding suggested the possible inhibitory effects of Cepharanthine and Glucosamine during SARS-CoV-2 infection and the subsequent inflammatory cytokine storm.

Citing Articles

SARS-CoV-2 Modulation of HIV Latency Reversal in a Myeloid Cell Line: Direct and Bystander Effects.

Jarmoluk P, Sviercz F, Cevallos C, Freiberger R, Lopez C, Poli G Viruses. 2024; 16(8).

PMID: 39205284 PMC: 11359691. DOI: 10.3390/v16081310.


Impact of the SARS-CoV-2 Spike Protein on the Innate Immune System: A Review.

Bocquet-Garcon A Cureus. 2024; 16(3):e57008.

PMID: 38549864 PMC: 10973921. DOI: 10.7759/cureus.57008.


Inhibition of porcine deltacoronavirus entry and replication by Cepharanthine.

Sun Y, Liu Z, Shen S, Zhang M, Liu L, Ghonaim A Virus Res. 2023; 340:199303.

PMID: 38145807 PMC: 10792575. DOI: 10.1016/j.virusres.2023.199303.


Dissecting the molecular mechanism of cepharanthine against COVID-19, based on a network pharmacology strategy combined with RNA-sequencing analysis, molecular docking, and molecular dynamics simulation.

Liu J, Sun T, Liu S, Liu J, Fang S, Tan S Comput Biol Med. 2022; 151(Pt A):106298.

PMID: 36403355 PMC: 9671524. DOI: 10.1016/j.compbiomed.2022.106298.


A New Butyrate Releaser Exerts a Protective Action against SARS-CoV-2 Infection in Human Intestine.

Paparo L, Maglio M, Cortese M, Bruno C, Capasso M, Punzo E Molecules. 2022; 27(3).

PMID: 35164139 PMC: 8838168. DOI: 10.3390/molecules27030862.

References
1.
Garcia-Del-Barco D, Risco-Acevedo D, Berlanga-Acosta J, Martos-Benitez F, Guillen-Nieto G . Revisiting Pleiotropic Effects of Type I Interferons: Rationale for Its Prophylactic and Therapeutic Use Against SARS-CoV-2. Front Immunol. 2021; 12:655528. PMC: 8033157. DOI: 10.3389/fimmu.2021.655528. View

2.
Fan H, Wang L, Liu W, An X, Liu Z, He X . Repurposing of clinically approved drugs for treatment of coronavirus disease 2019 in a 2019-novel coronavirus-related coronavirus model. Chin Med J (Engl). 2020; 133(9):1051-1056. PMC: 7147283. DOI: 10.1097/CM9.0000000000000797. View

3.
Kim S, Cohen B, Novick D, Rubinstein M . Mammalian type I interferon receptors consists of two subunits: IFNaR1 and IFNaR2. Gene. 1997; 196(1-2):279-86. DOI: 10.1016/s0378-1119(97)00240-0. View

4.
Komuro I . SARS-CoV-2 surreptitiously injures the heart of Japanese: echocardiography is useful in evaluating cardiac damage. Glob Health Med. 2021; 3(2):60-61. PMC: 8071688. DOI: 10.35772/ghm.2021.01035. View

5.
Di Giacomo S, Mercatelli D, Rakhimov A, Giorgi F . Preliminary report on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Spike mutation T478K. J Med Virol. 2021; 93(9):5638-5643. PMC: 8242375. DOI: 10.1002/jmv.27062. View